Chartered Group: EU regulatory hurdles push Japanese asset managers toward EU-authorized fund platforms
Bitget2026/10/13 07:14- Chartered Group analysis flags EU market-access rules as the main constraint on Japanese asset managers’ European expansion.
- EU has not activated AIFMD third-country passport, forcing reliance on uneven national private placement regimes for alternative funds.
- Preferred entry model uses an EU-authorized management company platform, keeping regulatory responsibility in Europe while delegating portfolio management to Japan.
- Germany highlighted for institutional entry via Spezialfonds, with EUR 2.287 trillion AUM at end-2025.
- Report pegs European opportunity at EUR 34.4 trillion AUM at end-September 2025, with cross-border management already widespread.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korean think tanks significantly raise 2027 economic growth forecasts, betting on continued AI chip boom
The Korea Development Institute (KDI) raised its economic growth forecast for this year and next on Wednesday, betting that the global artificial intelligence (AI) boom will continue to drive semiconductor exports and investment, helping the South Korean economy maintain its growth momentum.
SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”
SQM.US still reports seeing "encouraging" potential demand trends.
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.
According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years
Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.
